A Review of Data Supporting the Approval of Aducanumab for Alzheimer Disease

Video

Findings from the 2 pivotal phase 3 trials had mixed results on cognitive benefit, although they found a positive reduction in amyloid plaque in patients' brains.

In an interview with Pharmacy Times, Pamela Spicer, senior analyst at Datamonitor with Informa Pharma Intelligence, reviewed the 2 pivotal phase 3 clinical trials supporting the FDA's recent approval of aducanumab. Notably, Spicer said 1 trial had a positive trend while the second trial had a negative trend, which resulted in the early cessation of both trials.

The findings had mixed results on cognitive benefit, although they found a positive reduction in amyloid plaque in patients' brains. Based on this, officials with the FDA approved the drug, Spicer said.

Related Videos
pharmacy oncology, Image Credit: © Konstantin Yuganov - stock.adobe.com
Mayo Clinic oncology pharmacy
Testicular cancer and prostate cancer concept. | Image Credit: kenchiro168 - stock.adobe.com
Medicine tablets on counting tray with counting spatula at pharmacy | Image Credit: sutlafk - stock.adobe.com
Capsules medicine and white medicine bottles on table | Image Credit: Satawat - stock.adobe.com
Human cell or Embryonic stem cell microscope background | Image Credit: Anusorn - stock.adobe.com
Concept of health care, pharmaceutical business, drug prices, pharmacy, medicine and economics | Image Credit: Oleg - stock.adobe.com
Bottle and scattered pills on color background, top view | Image Credit: New Africa - stock.adobe.com
pharmacy | Image Credit: Diego Cervo - stock.adobe.com
© 2024 MJH Life Sciences

All rights reserved.